The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry-Reference-Cited by-同舟云学术

The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry

Published:2021-12 Issue: Volume:75 Page:102045
ISSN:1877-7821
Container-title:Cancer Epidemiology
language:en
Short-container-title:Cancer Epidemiology

Author:

Pavlidis Nicholas,Rassy Elie^ORCID,Vermorken Jan B.,Assi Tarek,Kattan Joseph,Boussios Stergios^ORCID,Smith-Gagen Julie

Funder

University of Utah

Huntsman Cancer Institute

National Institutes of Health

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Epidemiology

Reference24 articles.

1. Cancer of unknown primary site;Pavlidis;Lancet Lond. Engl.,2012

2. Progress in refining the clinical management of cancer of unknown primary in the molecular era;Rassy;Nat. Rev. Clin. Oncol.,2020

3. The diagnostic challenges of patients with carcinoma of unknown primary;Rassy;Expert Rev. Anticancer Ther.,2020

4. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions;Kuhn;J. Pathol.,2012

5. Serous papillary peritoneal carcinoma: unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review;Pentheroudakis;Crit. Rev. Oncol. Hematol.,2010

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer;Future Oncology;2024-08-19

2. Cardiovascular adverse events associated with PARP inhibitors for ovarian cancer: a real world study (RWS) with Bayesian disproportional analysis based on the FDA adverse event reporting system (FAERS);Expert Opinion on Drug Safety;2024-08-12

3. Is the Homologous Recombination Repair Mutation Defined by a 15-Gene Panel Associated with the Prognosis of Epithelial Ovarian Cancer?;Molecular Diagnosis & Therapy;2024-07-05

4. Prognostic Value of Ki67 in Epithelial Ovarian Cancer: Post-Neoadjuvant Chemotherapy Ki67 Combined with CA125 Predicting Recurrence;Cancer Management and Research;2024-07

5. Real-world TRAE association between niraparib and platinum-based chemotherapy;Frontiers in Oncology;2024-06-17